Tests angiotensin-(1-7) in adults with obesity and high blood pressure
Tests angiotensin-(1-7) in adults with obesity and high blood pressure.
Plain-language title generated from the registry record
Registry title: Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Key facts
- Where
- Hershey, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06482853, who can take part
Where in United States
- Penn State Milton S. Hershey Medical CenterHershey, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Milton S. Hershey Medical Center
- Trial code
- NCT06482853
- Record updated
- 24 September 2026
- Original description
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.Read full original descriptionShow less
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Inclusion: Men and women of all races; Age 18 to 65 years; Body mass index (BMI) between 30-45 kg/m2; Pre-hypertension (defined as two or more seated blood pressure readings >120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings >130/80 mmHg or use of antihypertensive medications); Capable of giving informed consent; Fluent in written and spoken English; Satisfactory history and physical exam.
Exclusion: Taking more than two antihypertensive medications; Women taking hormone replacement therapy within 6 months; Alcohol or drug abuse; Treatment with drugs increasing sympathetic activity [e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants]; Treatment with phosphodiesterase-5 inhibitors; Treatment with anticoagulants (e.g. warfarin); Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month); Treatment with any investigational drug in the 1-month preceding the study; Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease); Decisional impairment; History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack); History or presence of immunological or hematological disorders; Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications); Impaired hepatic function [aspartate aminotransferase (AST) or alanine transaminase (ALT) levels >2 times upper limit of normal range]; Impaired renal function (serum creatinine >2.0 mg/dl); Age ≤ 17 or ≥ 66 years; Pregnant or nursing women; Prisoners; Current smokers; Highly trained athletes; Subjects with >5% weight change in the past 3 months; BMI > 45 kg/m2; Anemia; Inability to give, or withdraw, informed consent.